Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- SOFI +8.4%, JKS +7%, XPO +6.5%, SJW +3.5%, MCD +3%, BGC +2.6%, PSO +2.4%
Other news:
- MIRO +225% (United Therapeutics (UTHR) to acquire Miromatrix for $3.25 per share and an additional $1.75 per share in cash upon the achievement of a clinical development milestone)
- MGTX +30.3% (announces $30 million strategic investment from Sanofi (SNY); company pursuing multiple additional strategic opportunities)
- SRC +12.6% (Realty Income (O) to acquire Spirit Realty Capital in $9.3 billion transaction)
- MX +7.5% (Introduces 6th-Generation 600V SJ MOSFET Developed with Cutting-Edge Microfabrication Technology)
- TRML +7.2% (Pfizer discloses 6.26% passive stake in Tourmaline Bio)
- LITE +3.4% (to acquire Cloud Light Technology Limited for transaction value of approx. $750 mln)
- MITT +3.1% (ISS Recommends AG Mortgage Investment Trust Stockholders Vote "FOR" the Proposed Merger With Western Asset Mortgage Capital Corporation)
- COIN +1.9% (positive Barron's article)
- LLY +1.8% (announces robust weight loss efficacy multiple metabolic benefits and favorable safety profile of higher dose 9 mg mazdutide (IBI362) after 48-week treatment in phase 2 study for obesity)
- FSM +1.7% (receives positive decision from Mexican Court which reinstates the San Jose Mine environmental impact authorization)
- STLA +1.6% (Stellantis and UAW reach tentative agreement)
- DOC +1.6% (Healthpeak and Physicians Realty Trust (DOC) to combine in an all-stock merger of equals valued at approximately $21 billion)
- AVGO +1.5% (Broadcom and VMware (VMW) provide update on pending transaction)
- DWAC +1.4% (announced filing of amended annual report marking an important milestone in preparation for the expected S-4 Filing)
- OMC +1.3% (acquires Flywheel Digital for $835 mln)
- GSK +1.3% (reports Phase III RUBY trial of Jemperli plus chemotherapy met endpoint of overall survival in patients with primary advanced or recurrent endometrial cancer)
- VMW +1.3% (Broadcom and VMware (VMW) provide update on pending transaction)
- NVS +1.2% (reports investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy)
Analyst comments:
- GOLF +2% (upgraded to Buy from Neutral at Compass Point)
- NWE +1.3% (upgraded to Overweight from Equal Weight at Wells Fargo)
- ABBV +1% (upgraded to Overweight from Equal Weight at Barclays)